Xience Versus Synergy in Left Main PCI
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 818 participants.
Also called NCT02303717
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 818 participants
- Registry
-
NCT02303717
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT02303717. Randomized; single masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Xience Versus Synergy in Left Main PCI
- Acronym
- IDEAL-LM
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Percutaneous coronary intervention
- Intervention (Drug)
- Dual antiplatelet therapy
- Lead sponsor
- NHS National Waiting Times Centre Board
- Collaborator
- Boston Scientific Corporation
- Collaborator
- Venn Life Sciences
- Collaborator
- Cardialysis B.V.
- Collaborator
- Diagram B.V.
Record details
- Record id
cardio:ct-nct02303717- Content hash
7aec4a17e0dc5b63cdcbc81ff656eeedf374ba55ed383f5ccec7a3c1bf7e0a45